Comparative Effectiveness of Health Interventions: Strategies to Change Policy and Practice
October 17-18, 2007 / Methodology Preconference: October 16, 2007
ECRI Institute's 15th Annual Conference
Comparative effectiveness is being weighed as a major policy initiative by federal policy makers and many constituencies within healthcare. It may have sweeping implications for how we evaluate and pay for competing approaches to patient care.
ECRI Institute's 15th Annual Conference brought together policymakers and practitioners from both inside the Beltway and across the nation. We sought greater insight into methods, management, diffusion to policy and practice, and to underlying thinking among multiple constituencies. We asked tough questions about comparative effectiveness and sought answers with the help of the nation's leading experts in this emerging field.
Visit our Comparative Effectiveness Resource Center to learn more about the issues explored at our 15th Annual Conference. This free educational Web site includes:
- Exclusive Conference Report
- Recordings of conference sessions
- Proposed legislation on comparative effectiveness
- Comparative effectiveness links, news, and more
Our attendees interacted with the nation’s leading healthcare authorities, including:
- Chief medical officers of FDA, CMS, major insurers
- Presidents/CEOs of the American College of Cardiology, Consumers Union (publisher of Consumer Reports), and AARP
- Directors of MedPAC, the Congressional Budget Office and the leading public sector health services research agency
- Policy advisors to several U.S. Presidents; the senior advisor to House Speaker Nancy Pelosi
- Senior decision makers from industry, business, state government, consumer advocacy and the research community
- SESSION 1: Making the Case for Comparative Effectiveness
- SESSION 2: Who Needs to Do What to Make CE Effective?
- SESSION 3: Will the Public Accept CE, and What Will Policy Makers Do?
Speakers and Moderators
- Stuart Altman, PhD, Professor of National Health Policy, Heller Graduate School of Social Policy and Management, Brandeis University
- Grant Bagley, MD, JD, Partner, Arnold and Porter, LLP
- Troyen Brennan, MD, JD, MPH, Chief Medical Officer, Aetna, Inc.
- Carolyn M. Clancy, MD, Director, Agency for Healthcare Research and Quality
- Lynn Etheredge, Consultant, Health Insurance Reform Project, George Washington University
- Brian Firth, MD, PhD, Worldwide Vice President, Health Affairs, Cordis Corporation
- Mark Gibson, Deputy Director, Center for Evidence-Based Policy, Oregon Health and Science University
- Roger Herdman, MD, Director, National Cancer Policy Forum, Institute of Medicine
- M. Carolina Hinestrosa, MA, MPH, Executive Vice President for Programs and Planning, National Breast Cancer Coalition
- Jeffrey C. Lerner, PhD, President and CEO, ECRI Institute
- Sharon Levine, MD, Assoc. Executive Director, The Permanente Medical Group, Inc.
- John C. Lewin, MD, Chief Executive Officer, American College of Cardiology
- Michael McGinnis, MD, MPP, Senior Scholar, Institute of Medicine
- Mark E. Miller, PhD, Executive Director, MedPAC
- William Novelli, MA, Chief Executive Officer, AARP
- Carmen Hooker Odom, Secretary of Health, North Carolina Department of Health and Human Services; Incoming President, Milbank Memorial Fund
- Peter Orszag, PhD, Director, Congressional Budget Office
- Steven D. Pearson, MD, MSc, FRCP, Director, Institute for Clinical and Economic Review, Harvard Medical School; Senior Fellow, America's Health Insurance Plans
- Wendell Primus, PhD, Policy Advisor to House Speaker Nancy Pelosi
- David Pryor, MD, Chief Medical Officer, Ascension Health
- James C. Robinson, PhD, Editor-in-Chief, Health Affairs
- Murray Ross, PhD, Director, Health Policy Analysis and Research, Kaiser Permanente Institute for Health Policy
- Cary Sennett, MD, PhD, FACP, Senior Vice President, Strategy and Clinical Analytics, American Board of Internal Medicine
- David Steel, PhD, Chief Executive, NHS Quality Improvement Scotland
- Barry Straube, MD, Director and Chief Clinical Officer, Office of Clinical Standards and Quality, Centers for Medicare and Medicaid Services
- Gail Shearer, Director, Health Policy Analysis, Consumers Union
- Donna-Bea Tillman, PhD, Director, Office of Device Evaluation, Center for Devices and Radiological Health, U.S. Food and Drug Administration
- Sean Tunis, MD, MSc, Director, Center for Medical Technology Policy
- Gail Wilensky, PhD, Senior Fellow, Project Hope
- Fiona Wilmot, MD, MPH, Director of Medical Policy, Pharmacy & Therapeutics and Transplant, Blue Shield of California
- Janet Woodcock, MD, Deputy Commissioner and Chief Medical Officer, U.S. Food and Drug Administration
- Charles M. Yarborough, MD, MPH, FACOEM, FACPM, Director, Health and Wellness Medical Strategies, Lockheed Martin Corporation
- Plus, more speakers to be announced
Our collaborators for this important conference were the Kaiser Permanente Institute for Health Policy, the Milbank Memorial Fund, Health Affairs, the Leonard Davis Institute of Health Economics, and the Employee Benefits Research Institute. Senior representatives from these organizations, and the Institute of Medicine, helped to plan and coordinate the program.
Porter Auditorium, Law Offices of Arnold & Porter, LLP, 555 Twelfth St., NW, Washington, DC 20004-1206